- Home
- BDTX vs NPV Comparison
BDTX vs NPV Comparison
Compare BDTX & NPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | NPV |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 185.7M |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | BDTX | NPV |
|---|---|---|
| Price | $1.86 | $9.31 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 548.2K | 123.0K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.90% |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $9.05 |
| 52 Week High | $4.94 | $11.81 |
Technical Indicators
Market Signals| Indicator | BDTX | NPV |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 25.45 |
| Support Level | $1.79 | N/A |
| Resistance Level | $1.90 | $11.61 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 21.43 | 30.61 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. The company mostly invests in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities, Housing/Multifamily, Transportation, and Others.